The Cancer Research KI Translational Seed Funding Grant 2026 provides seed funding for translational cancer research projects at Karolinska Institutet, with an emphasis on early‑stage work that bridges experimental and clinical cancer research and positions teams for larger external grants.
Eligibility Criteria:
- Applicants must be eligible to apply through Karolinska’s Cancer Research KI mechanisms (typically KI‑affiliated researchers; see call text on the KI site).
- Project must be clearly translational and cancer‑focused (e.g., moving mechanistic findings toward clinical application, biomarker validation, or patient‑oriented implementation).
- Other detailed eligibility requirements (e.g., PI status, co‑applicant rules) are specified in the full call on Cancer Research KI.
Funding Details:
- Mechanism: Seed funding for translational cancer projects; budget cap and allowable cost categories are defined in the Prisma call documentation linked from the KI page.
- Project start: June 1, 2026 (earliest start date).
- Funds are intended to support personnel time, consumables, and other direct costs necessary to generate data for follow‑on applications.
Deadline:
- Call opens: December 1, 2025.
- Application deadline: February 2, 2026.
Where to go for further information: